CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 479 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,701 | -56.1% | 179,620 | -44.6% | 0.00% | -62.5% |
| Q1 2024 | $22,086 | -31.8% | 324,031 | -37.3% | 0.01% | -27.3% |
| Q4 2023 | $32,362 | +39.6% | 516,965 | +1.2% | 0.01% | -21.4% |
| Q3 2023 | $23,186 | +10.7% | 510,832 | +36.9% | 0.01% | +7.7% |
| Q2 2023 | $20,953 | +0.3% | 373,203 | -19.2% | 0.01% | +30.0% |
| Q1 2023 | $20,884 | +12.6% | 461,759 | +1.2% | 0.01% | +25.0% |
| Q4 2022 | $18,547 | -99.7% | 456,277 | +319.5% | 0.01% | 0.0% |
| Q3 2022 | $7,108,000 | +439.7% | 108,766 | +402.4% | 0.01% | +700.0% |
| Q2 2022 | $1,317,000 | +19.0% | 21,649 | +22.8% | 0.00% | 0.0% |
| Q1 2022 | $1,107,000 | -48.4% | 17,624 | -37.8% | 0.00% | – |
| Q4 2021 | $2,146,000 | -42.0% | 28,342 | -14.2% | 0.00% | -100.0% |
| Q3 2021 | $3,697,000 | +8.7% | 33,030 | +57.1% | 0.00% | 0.0% |
| Q2 2021 | $3,402,000 | +381.9% | 21,024 | +262.5% | 0.00% | – |
| Q1 2021 | $706,000 | -81.4% | 5,800 | -76.6% | 0.00% | -100.0% |
| Q4 2020 | $3,789,000 | +239.2% | 24,747 | +85.3% | 0.00% | +100.0% |
| Q3 2020 | $1,117,000 | +13862.5% | 13,357 | +11933.3% | 0.00% | – |
| Q2 2020 | $8,000 | +33.3% | 111 | -25.0% | 0.00% | – |
| Q1 2020 | $6,000 | -98.1% | 148 | -97.2% | 0.00% | – |
| Q4 2019 | $324,000 | -43.0% | 5,309 | -61.7% | 0.00% | – |
| Q3 2019 | $568,000 | +23.7% | 13,877 | +42.7% | 0.00% | – |
| Q2 2019 | $459,000 | -13.1% | 9,726 | -34.3% | 0.00% | – |
| Q1 2019 | $528,000 | +279.9% | 14,799 | +203.3% | 0.00% | – |
| Q4 2018 | $139,000 | -74.3% | 4,879 | -59.9% | 0.00% | – |
| Q3 2018 | $541,000 | -87.9% | 12,181 | -84.0% | 0.00% | -100.0% |
| Q2 2018 | $4,481,000 | +35.1% | 76,271 | +5.1% | 0.00% | +33.3% |
| Q1 2018 | $3,318,000 | +821.7% | 72,600 | +374.5% | 0.00% | – |
| Q4 2017 | $360,000 | +70.6% | 15,300 | +29.0% | 0.00% | – |
| Q3 2017 | $211,000 | – | 11,864 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |